EUVIMEDEUVIMED entdecken
Klinische Studie

Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study

Taku Yamada, Taichi Minami, Masayo Yamada, Yasuo Terauchi

Endocrine Journal · 2023

DOI: 10.1507/endocrj.ej23-0186 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Endocrine Journal, 2023. Verfasst von Taku Yamada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama 234-0054, Japan. Hauptthemen laut MEDLINE: Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms, Diabetes Mellitus, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be related to HbA1c levels. We hypothesized that the CA19-9 cut-off levels would differ between patients with poorly controlled diabetes. This real-world trial was designed to test our hypotheses. This was a retrospective cohort study. All inpatients with poorly controlled diabetes had mean HbA1c levels of 10.0% and were divided into three groups: those with pancreatic cancer (PC group, N = 20), those with IPMN (IPMN group, N = 55), and those with neither (NC group, N = 985). Serum CA19-9 levels in the PC group were significantly higher than in the IPMN and NC groups (p 98.4 U/mL, most likely due to hepatocellular carcinoma and esophageal cancer. CA19-9 cut-off levels were thought to be 98.4 U/mL. However, we should keep in mind that the sensitivity and specificity were not 100%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic Intraductal NeoplasmsPancreatic NeoplasmsDiabetes MellitusCarcinoma, Pancreatic DuctalHumansCA-19-9 AntigenRetrospective StudiesGlycated HemoglobinBiomarkers, Tumor

Stichwörter der Autor:innen

Carbohydrate antigen 19-9 (CA19-9)Diabetes mellitusPancreatic cancer

Substanzen

CA-19-9 AntigenGlycated HemoglobinBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Nanbu Hospital, Yokohama 234-0054, Japan.
  • Department of Internal Medicine, Division of Endocrinology and Metabolism, Yokohama Minami Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, Yokohama 236-0037, Japan.
  • Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
  • Department of Internal Medicine, Division of Metabolism and Endocrinology, Yokohama Sakae Kyosai Hospital, Federation of National Public Service Personnel Mutual Associations, Yokohama 247-0005, Japan.

Zitieren

APA

Yamada, T., Minami, T., Yamada, M., & Terauchi, Y. (2023). Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study. Endocrine Journal. https://doi.org/10.1507/endocrj.ej23-0186

Vancouver

Yamada T, Minami T, Yamada M, Terauchi Y. Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study. Endocrine Journal. 2023. doi:10.1507/endocrj.ej23-0186

BibTeX
@article{Yamada2023,
  author = {Yamada, Taku and Minami, Taichi and Yamada, Masayo and Terauchi, Yasuo},
  title = {Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study},
  journal = {Endocrine Journal},
  year = {2023},
  doi = {10.1507/endocrj.ej23-0186}
}
Kostenlos starten →